Imatinib activity on Schistosoma mansoni
AUTOR(ES)
Katz, Naftale, Couto, Flávia Fernanda Bubulo, Araújo, Neusa
FONTE
Mem. Inst. Oswaldo Cruz
DATA DE PUBLICAÇÃO
2013-11
RESUMO
Imatinib, a drug used for treatment of human chronic myeloid leukaemia, due to its activity against protein kinases, has been also evaluated in vitro against Schistosoma mansoni showing high schistosomicidal activity. In the present experiments imatinib activity in vitro was confirmed at the doses of 25 µM, 50 µM and 100 µM. The first drug activity observed with the lower dose was interruption of egg-laying and with the higher dosages was the death of the worms. In mice infected with S. mansoni no activity was found even with 1,000 mg/kg/day, 500 mg/kg/day, single oral dose or when administered for three consecutive days. This is another example of the difference of results related to in vitro and in vivo trials using S. mansoni worms.
Documentos Relacionados
- Activity of praziquantel on in vitro transformed Schistosoma mansoni sporocysts
- Ação de cordia verbenacea sobre schistosoma mansoni
- Schistosoma mansoni larvicidal activity of murine bronchoalveolar lavage cells.
- Antischistosomal activity of a calcium channel antagonist on schistosomula and adult Schistosoma mansoni worms
- Scientific progress versus ecological influence on Schistosoma mansoni transmission